Japan Generics Policy To Spark Mergers Among Makers
This article was originally published in PharmAsia News
Japan's inauguration of a generics promotion campaign in April is expected to lead to an increase in consolidations by makers of the drugs. The Japan generics market, counted at $3.41 billion in 2006, is expected to grow sharply after the new policy gets under way. The policy spurs a need for generics makers to become bigger so they can serve a larger market. Nichiiko Pharmaceutical-Teikoko Medix KK, Zydus Cadilla Group-Nippon Universal Pharmaceutical and India's Lupin and Kyowa Pharmaceutical are examples of recent mergers. (Click here for more - a subscription may be required)
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.